- Market Capitalization, $K 30,803
- Shares Outstanding, K 19,873
- Annual Sales, $ 0 K
- Annual Income, $ -25,450 K
- 60-Month Beta 2.01
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 0.40
|Period||Period Low||Period High||Performance|
| || |
-0.0506 (-3.24%)since 09/25/20
| || |
-0.5406 (-26.37%)since 07/24/20
| || |
-1.1606 (-43.47%)since 10/25/19
Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.
Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.
Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.
, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that a sufficient number of patients (~65% of the original...
Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.
Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.
Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.
, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended and provides...
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.